329 related articles for article (PubMed ID: 17505009)
1. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
2. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
5. A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model.
Guo R; Yang Y; Zhang D; Du J; Zhu X; Liu Y; Yang F; Lin J
Int J Pharm; 2021 Jan; 592():120037. PubMed ID: 33161038
[TBL] [Abstract][Full Text] [Related]
6. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
7. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
8. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 Nov; 13(21):6486-93. PubMed ID: 17975161
[TBL] [Abstract][Full Text] [Related]
9. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
10. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
[TBL] [Abstract][Full Text] [Related]
11. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
14. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
16. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential.
Entwistle J; Brown JG; Chooniedass S; Cizeau J; MacDonald GC
Cancer Biother Radiopharm; 2012 Nov; 27(9):582-92. PubMed ID: 22856424
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
19. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
20. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]